Massachusetts Society of Clinical Oncologists - A practice-changing update to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer

"The voice for cancer physicians and their patients in Massachusetts."

Home
Resources
For Professionals
Drug Updates
A practice-changing update to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer

A practice-changing update to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer

01 Feb 2023 8:32 AM | Katy Monaco (Administrator)

On January 27, 2023, the National Comprehensive Cancer Network® (NCCN®) revised its guidelines—now ribociclib (KISQALI®) is the only CDK4/6 inhibitor in combination with an AI designated as a Category 1 Preferred regimen in first-line HR+/HER2- mBC.1,2

Can we set up some time to further explore this major update and review the data that made the NCCN differentiate ribociclib (KISQALI) for first-line use in combination with an AI? Please feel free to contact me at (802) 735-7859 or via email.

See the evidence that drove the update

Click here to read the NCCN Guidelines®.

Click here for full Prescribing Information for KISQALI.

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329 | email: msco@mms.org